0.9059 USD
+0.01 (+0.76%)
0.916 USD
+0.01 (+1.11%)
We assign a fundamental rating of 2 out of 10 to TLRY. TLRY was compared to 192 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, TLRY is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TLRY had negative earnings in the past year.
TLRY had a negative operating cash flow in the past year.
In the past 5 years TLRY always reported negative net income.
In the past 5 years TLRY reported 4 times negative operating cash flow.
1.2 Ratios
The Return On Assets of TLRY (-103.13%) is worse than 78.13% of its industry peers.
TLRY's Return On Equity of -139.41% is on the low side compared to the rest of the industry. TLRY is outperformed by 68.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -103.13% | ||
| ROE | -139.41% | ||
| ROIC | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TLRY's Gross Margin of 28.69% is in line compared to the rest of the industry. TLRY outperforms 55.73% of its industry peers.
TLRY's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TLRY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
The number of shares outstanding for TLRY has been increased compared to 5 years ago.
Compared to 1 year ago, TLRY has a worse debt to assets ratio.
2.2 Solvency
TLRY has an Altman-Z score of -1.60. This is a bad value and indicates that TLRY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.60, TLRY is in line with its industry, outperforming 45.31% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that TLRY is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.18, TLRY perfoms like the industry average, outperforming 47.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.6 |
ROIC/WACCN/A
WACC7.91%
2.3 Liquidity
TLRY has a Current Ratio of 2.62. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TLRY (2.62) is comparable to the rest of the industry.
TLRY has a Quick Ratio of 1.56. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of TLRY (1.56) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
The earnings per share for TLRY have decreased strongly by -648.00% in the last year.
TLRY shows a small growth in Revenue. In the last year, the Revenue has grown by 2.31%.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.52% yearly.
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)2.31%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
3.2 Future
Based on estimates for the next years, TLRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.44% on average per year.
TLRY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.31% yearly.
EPS Next Y97.21%
EPS Next 2Y40.83%
EPS Next 3Y26.48%
EPS Next 5Y15.44%
Revenue Next Year3.68%
Revenue Next 2Y4.08%
Revenue Next 3Y4.04%
Revenue Next 5Y4.31%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
78.65% of the companies in the same industry are more expensive than TLRY, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 24.16 |
4.3 Compensation for Growth
TLRY's earnings are expected to grow with 26.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.83%
EPS Next 3Y26.48%
5. Dividend
5.1 Amount
TLRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.9059
+0.01 (+0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.86%
Inst Owner Change21.16%
Ins Owners0.36%
Ins Owner Change3.78%
Market Cap1.02B
Revenue(TTM)830.77M
Net Income(TTM)-2.15B
Analysts71.25
Price Target1.89 (108.63%)
Short Float %9.01%
Short Ratio1.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2631.48%
Min EPS beat(2)-5362.97%
Max EPS beat(2)100%
EPS beat(4)1
Avg EPS beat(4)-1385.84%
Min EPS beat(4)-5362.97%
Max EPS beat(4)100%
EPS beat(8)2
Avg EPS beat(8)-708.23%
EPS beat(12)2
Avg EPS beat(12)-746.7%
EPS beat(16)4
Avg EPS beat(16)-606.4%
Revenue beat(2)1
Avg Revenue beat(2)-3.41%
Min Revenue beat(2)-7.23%
Max Revenue beat(2)0.41%
Revenue beat(4)1
Avg Revenue beat(4)-6.19%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)0.41%
Revenue beat(8)1
Avg Revenue beat(8)-5.71%
Revenue beat(12)2
Avg Revenue beat(12)-3.59%
Revenue beat(16)2
Avg Revenue beat(16)-3.93%
PT rev (1m)82.7%
PT rev (3m)93.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.86%
EPS NY rev (1m)1.18%
EPS NY rev (3m)61.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.59%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-0.11%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.22 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.66 | ||
| P/tB | 1.33 | ||
| EV/EBITDA | 24.16 |
EPS(TTM)-1.5
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.74
BVpS1.37
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -103.13% | ||
| ROE | -139.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.69% | ||
| FCFM | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 6.5 | ||
| Cap/Depr | 30.45% | ||
| Cap/Sales | 4.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | -1.6 |
F-Score3
WACC7.91%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.01%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y97.21%
EPS Next 2Y40.83%
EPS Next 3Y26.48%
EPS Next 5Y15.44%
Revenue 1Y (TTM)2.31%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
Revenue Next Year3.68%
Revenue Next 2Y4.08%
Revenue Next 3Y4.04%
Revenue Next 5Y4.31%
EBIT growth 1Y28.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.7%
EBIT Next 3Y29.12%
EBIT Next 5Y17.36%
FCF growth 1Y-688.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-258.17%
OCF growth 3YN/A
OCF growth 5YN/A
TILRAY BRANDS INC / TLRY FAQ
Can you provide the ChartMill fundamental rating for TILRAY BRANDS INC?
ChartMill assigns a fundamental rating of 2 / 10 to TLRY.
What is the valuation status of TILRAY BRANDS INC (TLRY) stock?
ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (TLRY). This can be considered as Overvalued.
How profitable is TILRAY BRANDS INC (TLRY) stock?
TILRAY BRANDS INC (TLRY) has a profitability rating of 1 / 10.
How financially healthy is TILRAY BRANDS INC?
The financial health rating of TILRAY BRANDS INC (TLRY) is 3 / 10.